Eprodisate

Summary

Eprodisate (CHEMBL2111092) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 204.2 Da · C3H8O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111092
Name	Eprodisate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	428573
Molecular formula	C3H8O6S2
Molecular weight	204.2
InChIKey	MGNVWUDMMXZUDI-UHFFFAOYSA-N

SMILES: C(CS(=O)(=O)O)CS(=O)(=O)O

IUPAC name: propane-1,3-disulfonic acid

Also known as: Eprodisate, Eprodisato, Eprodisate disodiumÊ, Eprodisate disodiumÂ, EPRODISATE DISODIUM, EPRODISATE

Parent form; salt/anhydrous children: CHEMBL2107338

Patent coverage: 633 distinct patent families (1,915 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).